TD Cowen analyst Ryan Langston maintained a Hold rating on P3 Health Partners (PIII – Research Report) today and set a price target of $0.25.

P3 Health Partners backs FY25 revenue view $1.35B-$1.5B, consensus $1.4B Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

Q4 2024 Earnings Call Transcript March 27, 2025 P3 Health Partners Inc. misses on earnings expectations. Reported EPS is ...

Amir Bacchus; Co-Founder, Chief Medical Officer, Director; P3 Health Partners Inc Good day and welcome to the P3 Health Partners fourth-quarter 2024 earnings conference call. (Operator ...

Shares of P3 Health Partners were trading at $0.1829 as of March 25. Over the last 52-week period, shares are down 82.58%.

HENDERSON, Nev., April 02, 2025--(BUSINESS WIRE)--P3 Health Partners Inc. ("P3") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that it ...

P3 Health Partners' Q4 2024 earnings show 18% annual revenue growth and reaffirmed profitability goals for 2025.

Shares of P3 Health Partners stock opened at $0.19 on Tuesday. The business’s 50-day moving average price is $0.19 and its 200-day moving average price is $0.27. The firm has a market ...

Good day and welcome to the P3 Health Partners’ Fourth Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation ...

HENDERSON, Nev. - P3 Health Partners Inc. (NASDAQ:PIII) reported a wider-than-expected loss and revenue miss for the fourth quarter of 2024, sending shares down 2.7% in after-hours trading Thursday.